bs_bs_banner
Therapeutic Apheresis and Dialysis 2014; 18(5):373–374 doi: 10.1111/1744-9987.12268 © 2014 The Author Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis
Invited Editorial
Message From the New President of the Japanese Society for Dialysis Therapy ing residents, etc., and conducting nationwide “Blood purification seminars for young physicians” as well as holding “Seminars that cover dialysis therapy as a whole” even at academic meetings, and constructing a system that encourages young investigators will contribute to securing dialysis therapy personnel. As a means of promoting the academic activities of the JSDT, I will promote cooperation between the Statistical Survey Committee and the Academic Committee, and inform the world of the fruits of clinical research on dialysis therapy in Japan. Making all-case surveys the standard, I would like to strive to increase the recovery rate of questionnaire surveys as well as raise data cleaning efficiency, and to reflect the valuable data we have obtained from everyone in our academic activities. I would like to support the academic activities of clinical engineering technologists, nurses, pharmacists, and managerial dietitians, and consider plans so that they would be useful in team care. One of the problems with the treatment of endstage renal failure in Japan is that despite having the highest ratio of patients on dialysis to the total population in the world, an unbalanced situation prevails in which the proportion of patients on hemodialysis is higher than in Western countries, while the proportions on peritoneal dialysis and proportion who receive a kidney transplant are much lower. The availability of three treatment options, i.e., hemodialysis, peritoneal dialysis, and kidney transplantation, is important to performing balanced renal failure care. There is a report that kidney transplantation is explained as a treatment to only about 30% of patients, and that peritoneal dialysis is explained to only about 50%. In collaboration with the Japanese Society of Nephrology, the Japan Society for Transplantation, the Japanese Society for Clinical Renal Transplantation, and the Japanese Society for Peritoneal Dialysis, I will make an effort to conduct information and popularization activities in regard to these three treatment methods. The population of the Asian region is growing, and the position it occupies in the global economy is increasing. Because Japan occupies an important
At the board meeting of the Japanese Society for Dialysis Therapy (JSDT) held on June 12, 2014, I was selected to serve as the next president of the Society. I intend to strive for further development of the JSDT, which has a long history and has flourished thanks to the efforts of my predecessors. Japan is about to confront an unprecedented super-aged society in the world. Even the pathology associated with dialysis appears to become more complex with age, and because of that the most important task the JSDT has been charged with is approaching dialysis therapy with a view to the future. I would like to improve the prognosis of dialysis patients by undertaking effective measures to prevent and control complications while reexamining dialysis therapy for the elderly from the ground up and promoting home care. Returning the fruits of the Society’s activities to the public through such shifts in thinking in regard to dialysis therapy and contributing to Japan and the world through the medium of dialysis medicine are missions of the JSDT. I would like to promote advances in technology and research and the dissemination of knowledge related to dialysis medicine in order to undertake the healthcare of the approximately 310,000 end-stage kidney failure patients nationwide. First, I think it is important to foster human resources. The shortage of physicians engaged in dialysis therapy has become a problem. To improve the quality of dialysis therapy, I am hoping that targeting young physicians, includ373
374
Invited Editorial
corner of the Asian region, I think it is very important to establish its leadership in Asia. It will be necessary to strengthen exchanges in the Asian region, and make efforts to raise the level of dialysis therapy. I will continue plans for young Asian dialysis physicians as part of international academic exchanges, and I think further improving such activities and increasing closer personnel exchanges will be a future task. As I stated at the beginning, the JSDT has become a large organization with over 16000 members, and running the organization efficiently and expeditiously is a major problem. Doing so requires activation of all of the standing committees and collaboration with related societies. Ultimately, I think that contributing to society through dialysis medicine determines the value of the Society. I consider informing the public of the fruits of the Society’s activities on its homepage in
Ther Apher Dial, Vol. 18, No. 5, 2014
an easy to understand manner to be a very important mission of the JSDT. Fulfilling that mission will require broad support not only from the Society’s members but from the public as well. Since I would like to take an approach to advancing dialysis therapy in cooperation with large numbers of people, I ask for your cooperation. Finally, I intend to do all in my power to deal with all of these issues. I ask all of the members of the Society and all of the related academic societies, groups, and businesses for your support in achieving these goals. Kosaku Nitta, MD, PhD Department of Medicine, Kidney Center, Tokyo Women’s Medical University Tokyo, Japan Email: [email protected]
© 2014 The Author Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis
Therapeutic Apheresis and Dialysis 2014; 18(5):373–374 doi: 10.1111/1744-9987.12268 © 2014 The Author Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis
Invited Editorial
Message From the New President of the Japanese Society for Dialysis Therapy ing residents, etc., and conducting nationwide “Blood purification seminars for young physicians” as well as holding “Seminars that cover dialysis therapy as a whole” even at academic meetings, and constructing a system that encourages young investigators will contribute to securing dialysis therapy personnel. As a means of promoting the academic activities of the JSDT, I will promote cooperation between the Statistical Survey Committee and the Academic Committee, and inform the world of the fruits of clinical research on dialysis therapy in Japan. Making all-case surveys the standard, I would like to strive to increase the recovery rate of questionnaire surveys as well as raise data cleaning efficiency, and to reflect the valuable data we have obtained from everyone in our academic activities. I would like to support the academic activities of clinical engineering technologists, nurses, pharmacists, and managerial dietitians, and consider plans so that they would be useful in team care. One of the problems with the treatment of endstage renal failure in Japan is that despite having the highest ratio of patients on dialysis to the total population in the world, an unbalanced situation prevails in which the proportion of patients on hemodialysis is higher than in Western countries, while the proportions on peritoneal dialysis and proportion who receive a kidney transplant are much lower. The availability of three treatment options, i.e., hemodialysis, peritoneal dialysis, and kidney transplantation, is important to performing balanced renal failure care. There is a report that kidney transplantation is explained as a treatment to only about 30% of patients, and that peritoneal dialysis is explained to only about 50%. In collaboration with the Japanese Society of Nephrology, the Japan Society for Transplantation, the Japanese Society for Clinical Renal Transplantation, and the Japanese Society for Peritoneal Dialysis, I will make an effort to conduct information and popularization activities in regard to these three treatment methods. The population of the Asian region is growing, and the position it occupies in the global economy is increasing. Because Japan occupies an important
At the board meeting of the Japanese Society for Dialysis Therapy (JSDT) held on June 12, 2014, I was selected to serve as the next president of the Society. I intend to strive for further development of the JSDT, which has a long history and has flourished thanks to the efforts of my predecessors. Japan is about to confront an unprecedented super-aged society in the world. Even the pathology associated with dialysis appears to become more complex with age, and because of that the most important task the JSDT has been charged with is approaching dialysis therapy with a view to the future. I would like to improve the prognosis of dialysis patients by undertaking effective measures to prevent and control complications while reexamining dialysis therapy for the elderly from the ground up and promoting home care. Returning the fruits of the Society’s activities to the public through such shifts in thinking in regard to dialysis therapy and contributing to Japan and the world through the medium of dialysis medicine are missions of the JSDT. I would like to promote advances in technology and research and the dissemination of knowledge related to dialysis medicine in order to undertake the healthcare of the approximately 310,000 end-stage kidney failure patients nationwide. First, I think it is important to foster human resources. The shortage of physicians engaged in dialysis therapy has become a problem. To improve the quality of dialysis therapy, I am hoping that targeting young physicians, includ373
374
Invited Editorial
corner of the Asian region, I think it is very important to establish its leadership in Asia. It will be necessary to strengthen exchanges in the Asian region, and make efforts to raise the level of dialysis therapy. I will continue plans for young Asian dialysis physicians as part of international academic exchanges, and I think further improving such activities and increasing closer personnel exchanges will be a future task. As I stated at the beginning, the JSDT has become a large organization with over 16000 members, and running the organization efficiently and expeditiously is a major problem. Doing so requires activation of all of the standing committees and collaboration with related societies. Ultimately, I think that contributing to society through dialysis medicine determines the value of the Society. I consider informing the public of the fruits of the Society’s activities on its homepage in
Ther Apher Dial, Vol. 18, No. 5, 2014
an easy to understand manner to be a very important mission of the JSDT. Fulfilling that mission will require broad support not only from the Society’s members but from the public as well. Since I would like to take an approach to advancing dialysis therapy in cooperation with large numbers of people, I ask for your cooperation. Finally, I intend to do all in my power to deal with all of these issues. I ask all of the members of the Society and all of the related academic societies, groups, and businesses for your support in achieving these goals. Kosaku Nitta, MD, PhD Department of Medicine, Kidney Center, Tokyo Women’s Medical University Tokyo, Japan Email: [email protected]
© 2014 The Author Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis
